Decline of substance P levels after stress management with cognitive behaviour therapy in women with the fibromyalgia syndrome
| Autor: | Kurt Svärdsudd, Karin Björkegren, Gunilla Burell, Per Kristiansson, Bo Karlsson, Fred Nyberg |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Stress management
medicine.medical_specialty Fibromyalgia Psychometrics Pain Substance P Intervention group law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Surveys and Questionnaires medicine Humans 030212 general & internal medicine Cognitive Behavioral Therapy business.industry Middle Aged medicine.disease Cognitive behaviour therapy Anesthesiology and Pain Medicine Fibromyalgia syndrome chemistry Montgomery–Åsberg Depression Rating Scale Physical therapy Female Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | Scandinavian journal of painReferences. 19(3) |
| ISSN: | 1877-8879 |
| Popis: | Background and aims Substance P (CSF-SP) is known to be elevated in females with fibromyalgia syndrome (FMS). The aims of this study were to evaluate the effect of cognitive behaviour therapy (CBT) on plasma SP levels in women with FMS and to find possible clinical behavioural correlates to plasma SP level changes. Methods Forty-eight women with FMS were randomly allocated into two groups. Group 1 received the CBT treatment intervention over the course of 6 months while group 2 was waitlisted. CBT was given with a protocol developed to diminish stress and pain. After 6 months, group 2 was given the same CBT treatment as well. All were followed up 1 year after the start of CBT treatment. This approach allowed for two analytical designs – a randomised controlled trial (RCT) (n=24 vs. n=24) and a before-and-after treatment design (n=48). All women were repeatedly evaluated by the West Haven-Yale Multidimensional Pain Inventory (MPI) and three other psychometric questionnaires and plasma SP was analysed. Results In the RCT design, the plasma SP level was 8.79 fmol/mL in both groups at the start of the trial, after adjustment for initial differences. At the end of the RCT, the plasma SP level was 5.25 fmol/mL in the CBT intervention group compared to 8.39 fmol/mL in the control group (p=0.02). In the before-and-after design, the plasma SP was reduced by 33% (p Conclusions Plasma SP might be a marker of the effect of CBT in FMS associated with better coping strategies and reduced stress rather than a biochemical marker of pain. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|